Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ClinTec Starts Operations in Malawi

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Leading pharmaceutical company selects ClinTec as partner of choice in Africa and Asia.

ClinTec International has expanded its operations into Malawi, appointing its first highly experienced clinical research associates.

A top 5 pharmaceutical company with sales exceeding US$50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East. The global vaccines market has an estimated value of US$33.8 billion.

Africa is a pivotal region for the development of adult and paediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programmes.

The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.

Vaccine development faces its own challenges associated with local immunization recommendations as well as stringent cold chain management.

ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, whilst complying in full with international clinical research guidelines.

ClinTec, winner of the 2011 Queen’s Award for Enterprise, operates in over 40 countries to provide specialist clinical research personnel and support services to its clients, which includes 11 of the top 25 pharmaceutical companies.

ClinTec has grown organically since its inception in the UK in 1997, and has recently reported a 429 percent growth rate over the 5-year period from 2006 to 2011.

It was one of the first CROs to establish a presence in the Middle East and Africa and has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace.

Commenting on the opening of ClinTec’s Malawi operations, Dr Rabinder Buttar stated: “I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials. Despite the challenging economic conditions through which many of our clients are restructuring their organizations, ClinTec continues to grow and win major new business from pharma companies. The company is continuing to expand into interesting new regions for clinical research. As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!